0000914475-24-000082.txt : 20240229
0000914475-24-000082.hdr.sgml : 20240229
20240229185510
ACCESSION NUMBER: 0000914475-24-000082
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENEVICH ERIC
CENTRAL INDEX KEY: 0001643653
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24706154
MAIL ADDRESS:
STREET 1: C/O NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1709250893.xml
FORM 4
X0508
4
2024-02-28
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001643653
BENEVICH ERIC
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Commercial Officer
1
Common Stock
2024-02-28
4
M
0
53143
43.24
A
93759
D
Common Stock
2024-02-28
4
S
0
53143
134.6881
D
40616
D
Common Stock
2024-02-28
4
M
0
21857
79.02
A
62473
D
Common Stock
2024-02-28
4
S
0
21857
134.6881
D
40616
D
Non-Qualified Stock Option
43.24
2024-02-28
4
M
0
53143
43.24
D
2027-02-06
Common Stock
53143
0
D
Non-Qualified Stock Option
79.02
2024-02-28
4
M
0
21857
79.02
D
2032-01-31
Common Stock
21857
39360
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $133.82 to $136.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options will expire ten years from the date of grant on February 6, 2027.
The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-02-29